107.17
2.22 (2.12%)
| Previous Close | 104.95 |
| Open | 107.93 |
| Volume | 347,804 |
| Avg. Volume (3M) | 601,206 |
| Market Cap | 8,322,523,648 |
| Price / Book | 9.52 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Diluted EPS (TTM) | -4.42 |
| Current Ratio (MRQ) | 14.48 |
| Operating Cash Flow (TTM) | -203.80 M |
| Levered Free Cash Flow (TTM) | -98.58 M |
| Return on Assets (TTM) | -22.23% |
| Return on Equity (TTM) | -35.69% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Nuvalent, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | -3.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.50 |
|
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company’s operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.85% |
| % Held by Institutions | 110.02% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 158.00 (Baird, 47.43%) | Buy |
| Median | 145.00 (35.30%) | |
| Low | 126.00 (Canaccord Genuity, 17.57%) | Buy |
| Average | 144.22 (34.57%) | |
| Total | 9 Buy | |
| Avg. Price @ Call | 105.23 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 19 Dec 2025 | 145.00 (35.30%) | Buy | 103.80 |
| Truist Securities | 24 Nov 2025 | 140.00 (30.63%) | Buy | 109.53 |
| Baird | 18 Nov 2025 | 158.00 (47.43%) | Buy | 104.24 |
| Goldman Sachs | 18 Nov 2025 | 135.00 (25.97%) | Buy | 104.24 |
| Guggenheim | 18 Nov 2025 | 155.00 (44.63%) | Buy | 104.24 |
| HC Wainwright & Co. | 17 Nov 2025 | 155.00 (44.63%) | Buy | 108.00 |
| Leerink Partners | 17 Nov 2025 | 149.00 (39.03%) | Buy | 108.00 |
| Stifel | 17 Nov 2025 | 135.00 (25.97%) | Buy | 108.00 |
| Canaccord Genuity | 12 Nov 2025 | 126.00 (17.57%) | Buy | 97.03 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| NOCI DARLENE | - | 102.43 | -5,500 | -563,365 |
| Aggregate Net Quantity | -5,500 | |||
| Aggregate Net Value ($) | -563,365 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 102.43 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| NOCI DARLENE | Officer | 29 Jan 2026 | Automatic sell (-) | 5,500 | 102.43 | 563,365 |
| NOCI DARLENE | Officer | 29 Jan 2026 | Option execute | 5,500 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |